Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Phase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line chemotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
54 participants in 1 patient group
Loading...
Central trial contact
Joann Santmyer, RN; Colleen Apostol, RN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal